Nuwellis, Inc. — Director's Dealing 2019

Mar 12, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: CHF Solutions, Inc. (CHFS)
CIK: 0001506492
Period of Report: 2019-03-12

Reporting Person: ERB JOHN L (Director, CEO and President)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2019-03-12	Common Stock	P	9523	$5.25	Acquired	11615	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2019-03-12	Series 1 Warrant to Purchase Common Stock (right to buy)	$5.25	P	9523	Acquired	2024-03-12	Common Stock (9523)	Direct
2019-03-12	Series 2 Warrant to Purchase Common Stock (right to buy)	$5.25	P	9523	Acquired		Common Stock (9523)	Direct

Footnotes

F1: The reporting person purchased Class A Units, which consisted of one share of common stock, a Series 1 warrant to purchase one share of common stock, and a Series 2 warrant to purchase one share of common stock, in an underwritten public offering by the issuer at a price of $5.25 per unit. The offering closed on March 12, 2019.

F2: On January 2, 2019, the issuer effected a 1-for-14 reverse stock split of the issued and outstanding shares of its common stock. Upon effectiveness of the reverse stock split, every 14 shares of common stock was automatically converted into one share of common stock.

F3: The Series 2 warrant expires on the earlier of the eighteen-month anniversary of the date of issuance and the 30th trading day following public announcement by the issuer of receipt from the U.S. Food and Drug Administration of clearance or approval of a modification to the product label for the Aquadex FlexFlow system to include pediatric patients.